FLGT · Fulgent Genetics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.14M | - | $84.07M | $81.80M | $73.46M | - | $71.74M | $71.03M | $64.48M | - |
| Cost of Revenue | $49.65M | - | $48.56M | $47.37M | $45.12M | - | $44.97M | $44.54M | $42.38M | - |
| Gross Profit | $21.49M | - | $35.51M | $34.44M | $28.35M | - | $26.77M | $26.49M | $22.10M | - |
| R&D | $14.18M | - | $13.86M | $13.48M | $12.39M | - | $11.78M | $13.49M | $11.43M | - |
| SG&A | $27.68M | - | $23.34M | $26.39M | $25.29M | - | $20.95M | $21.33M | $21.49M | - |
| Total Operating Expenses | $56.11M | - | $50.86M | $54.15M | $48.14M | - | $43.85M | $45.40M | $43.90M | - |
| D&A | $6.00M | - | $3.90M | $3.90M | $5.92M | - | $5.92M | $6.31M | $6.66M | - |
| Operating Income | ($34.62M) | - | ($15.35M) | ($19.71M) | ($19.80M) | - | ($17.08M) | ($18.91M) | ($21.80M) | - |
| Interest Expense | $17.0K | - | $28.0K | $17.0K | ($249.0K) | - | $70.0K | - | - | - |
| Income Tax | ($704.0K) | - | ($683.0K) | ($2.26M) | $176.0K | - | ($3.84M) | ($2.12M) | ($327.0K) | - |
| Net Income | ($24.83M) | - | ($6.61M) | ($18.96M) | ($11.53M) | - | ($14.65M) | ($8.71M) | ($13.46M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.40M | $50.19M | $117.64M | $87.88M | $67.28M | $55.14M | $58.04M | $65.11M | $54.68M | $97.47M |
| Accounts Receivable | $69.28M | $84.76M | $71.19M | $77.19M | $71.48M | $69.02M | $57.31M | $56.57M | $52.06M | $51.13M |
| Inventory | $770.0K | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $21.13M | $18.65M | $18.09M | $18.89M | $18.24M | $18.36M | $19.80M | $19.87M | $19.62M | $15.36M |
| Current Assets | $479.04M | $550.49M | $507.37M | $428.73M | $416.78M | $353.57M | $326.54M | $399.10M | $386.51M | $507.85M |
| Total Assets | $1.16B | $1.21B | $1.21B | $1.20B | $1.21B | $1.22B | $1.23B | $1.23B | $1.23B | $1.24B |
| Current Liabilities | $90.13M | $84.97M | $72.43M | $71.33M | $65.92M | $72.90M | $73.99M | $75.75M | $75.95M | $73.02M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $112.22M | $106.81M | $93.81M | $88.20M | $82.97M | $90.81M | $98.86M | $103.39M | $103.24M | $102.04M |
| Stockholders' Equity | $1.05B | $1.11B | $1.13B | $1.12B | $1.13B | $1.13B | $1.14B | $1.13B | $1.13B | $1.14B |
| Retained Earnings | $505.13M | $529.95M | $553.37M | $559.98M | $578.94M | $590.47M | $596.36M | $611.00M | $619.71M | $633.17M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.10M | - | - | - | ($4.43M) | - | - | - | $7.27M | - |
| Investing Cash Flow | $10.94M | - | - | - | $27.73M | - | - | - | ($47.19M) | - |
| Financing Cash Flow | ($44.83M) | - | - | - | ($11.17M) | - | - | - | ($2.81M) | - |
| CapEx | $5.20M | - | - | - | $4.72M | - | - | - | $4.06M | - |
| Free Cash Flow | $1.90M | - | - | - | ($9.15M) | - | - | - | $3.21M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 30.2% | - | 42.2% | 42.1% | 38.6% | - | 37.3% | 37.3% | 34.3% | - |
| Operating margin | -48.7% | - | -18.3% | -24.1% | -26.9% | - | -23.8% | -26.6% | -33.8% | - |
| EBITDA margin | -40.2% | - | -13.6% | -19.3% | -18.9% | - | -15.6% | -17.7% | -23.5% | - |
| Net margin | -34.9% | - | -7.9% | -23.2% | -15.7% | - | -20.4% | -12.3% | -20.9% | - |
| Free cash flow margin | 2.7% | - | - | - | -12.5% | - | - | - | 5.0% | - |
| FCF / Net income | -0.08 | - | - | - | 0.79 | - | - | - | -0.24 | - |
| R&D / Revenue | 19.9% | - | 16.5% | 16.5% | 16.9% | - | 16.4% | 19.0% | 17.7% | - |
| SG&A / Revenue | 38.9% | - | 27.8% | 32.3% | 34.4% | - | 29.2% | 30.0% | 33.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.1% | - | -0.5% | -1.6% | -1.0% | - | -1.2% | -0.7% | -1.1% | - |
| Return on equity | -2.4% | - | -0.6% | -1.7% | -1.0% | - | -1.3% | -0.8% | -1.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.31 | 6.48 | 7.01 | 6.01 | 6.32 | 4.85 | 4.41 | 5.27 | 5.09 | 6.96 |
| Quick ratio | 5.31 | 6.48 | 7.01 | 6.01 | 6.32 | 4.85 | 4.41 | 5.27 | 5.09 | 6.96 |
| Cash ratio | 0.26 | 0.59 | 1.62 | 1.23 | 1.02 | 0.76 | 0.78 | 0.86 | 0.72 | 1.33 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2036.6x | - | -548.2x | -1159.6x | 79.5x | - | -244.0x | - | - | - |
| Equity multiplier | 1.10 | 1.09 | 1.08 | 1.07 | 1.07 | 1.08 | 1.08 | 1.09 | 1.09 | 1.09 |
| Liabilities / Assets | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | 0.06 | - | 0.07 | 0.07 | 0.06 | - | 0.06 | 0.06 | 0.05 | - |
| Inventory turnover | 64.48 | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 355d | - | 309d | 344d | 355d | - | 292d | 291d | 295d | - |
| Days inventory outstanding | 6d | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 155d | - | 136d | 146d | 148d | - | 161d | 163d | 169d | - |
| Cash conversion cycle | 206d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.5x | - | 0.6x | 0.5x | 0.5x | - | 0.6x | 0.5x | 0.6x | - |
| P / S | 6.9x | - | 8.3x | 7.4x | 7.1x | - | 9.2x | 8.3x | 10.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -3.2% | - | 17.2% | 15.2% | 13.9% | - | -15.3% | 4.7% | -2.5% | - |
| Revenue CAGR (3y) | 2.4% | - | -7.3% | -13.3% | -38.8% | - | -32.0% | -22.7% | -43.6% | - |
| Revenue CAGR (5y) | -27.7% | - | -3.7% | 36.5% | 56.8% | - | 47.3% | 53.2% | 64.4% | - |
| Gross profit growth (YoY) | -24.2% | - | 32.7% | 30.0% | 28.2% | - | -32.8% | 28.8% | 17.5% | - |
| Operating income growth (YoY) | -74.9% | - | 10.1% | -4.3% | 9.2% | - | - | 4.5% | 12.2% | - |
| Net income growth (YoY) | -115.3% | - | 54.9% | -117.6% | 14.4% | - | -11.8% | 22.4% | 12.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | -61.4% | - | - | - | - | - | - | - | 28.4% | - |
| Book value growth (YoY) | -6.9% | -1.9% | -1.1% | -1.4% | -0.2% | -0.3% | -9.6% | -10.1% | -10.6% | -10.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$322.67M totalLaboratory Services$322.22M · 99.9%
Therapeutic Development$447.0K · 0.1%
Geographic
$348.79M totalUS$296.55M · 85.0%
Non Us$26.12M · 7.5%
Other Countries$13.21M · 3.8%
CN$12.91M · 3.7%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Fulgent Genetics against the 5 most active filers in the same SIC group.